FDA Clears BMS’ Orencia In Juvenile Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Second indication comes with news of Repligen settlement.
You may also be interested in...
Big-Name Drugs Try New Roles In Rheumatism
Lilly’s Cymbalta performs well in major osteoarthritis trial.
Big-Name Drugs Try New Roles In Rheumatism
Lilly’s Cymbalta performs well in major osteoarthritis trial.
Genentech’s Rituxan Fails Against PPMS
Late-stage lupus trial is still a wild card for anti-B-cell therapy.